Seres Therapeutics (MCRB) Debt to Equity (2019 - 2024)
Historic Debt to Equity for Seres Therapeutics (MCRB) over the last 7 years, with Q2 2024 value amounting to -$1.18.
- Seres Therapeutics' Debt to Equity fell 12642.27% to -$1.18 in Q2 2024 from the same period last year, while for Jun 2024 it was -$1.18, marking a year-over-year decrease of 12642.27%. This contributed to the annual value of -$2.26 for FY2023, which is 14825.03% down from last year.
- According to the latest figures from Q2 2024, Seres Therapeutics' Debt to Equity is -$1.18, which was down 12642.27% from -$1.71 recorded in Q1 2024.
- In the past 5 years, Seres Therapeutics' Debt to Equity ranged from a high of $4.69 in Q4 2022 and a low of -$6.69 during Q3 2023
- Its 5-year average for Debt to Equity is -$0.0, with a median of $0.14 in 2020.
- As far as peak fluctuations go, Seres Therapeutics' Debt to Equity soared by 240373.84% in 2022, and later crashed by 98871.62% in 2023.
- Over the past 5 years, Seres Therapeutics' Debt to Equity (Quarter) stood at $0.14 in 2020, then skyrocketed by 32.9% to $0.19 in 2021, then soared by 2403.74% to $4.69 in 2022, then tumbled by 148.25% to -$2.26 in 2023, then surged by 48.0% to -$1.18 in 2024.
- Its Debt to Equity stands at -$1.18 for Q2 2024, versus -$1.71 for Q1 2024 and -$2.26 for Q4 2023.